188 related articles for article (PubMed ID: 24435895)
1. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
McNaughton R; Huet G; Shakir S
BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
[TBL] [Abstract][Full Text] [Related]
2. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons.
Mendes D; Alves C; Batel Marques F
Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204
[TBL] [Abstract][Full Text] [Related]
3. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
Lane S; Lynn E; Shakir S
BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
[TBL] [Abstract][Full Text] [Related]
5. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision.
Craveiro NS; Lopes BS; Tomás L; Almeida SF
Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381
[TBL] [Abstract][Full Text] [Related]
6. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
Onakpoya IJ; Heneghan CJ; Aronson JK
Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
[TBL] [Abstract][Full Text] [Related]
7. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
[TBL] [Abstract][Full Text] [Related]
8. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
[TBL] [Abstract][Full Text] [Related]
9. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
[TBL] [Abstract][Full Text] [Related]
10. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
[TBL] [Abstract][Full Text] [Related]
12. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
13. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
14. Post-approval safety issues with innovative drugs: a European cohort study.
Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
[TBL] [Abstract][Full Text] [Related]
15. Comparative regulatory performance on introduction & withdrawal of drugs in India and EU/internationally.
Kshirsagar NA; Bachhav SS
Int J Risk Saf Med; 2013; 25(4):235-8. PubMed ID: 24305562
[TBL] [Abstract][Full Text] [Related]
16. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.
Arnaiz JA; Carné X; Riba N; Codina C; Ribas J; Trilla A
Eur J Clin Pharmacol; 2001 Apr; 57(1):89-91. PubMed ID: 11372600
[TBL] [Abstract][Full Text] [Related]
17. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
[TBL] [Abstract][Full Text] [Related]
18. Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1328-1337. PubMed ID: 28691251
[TBL] [Abstract][Full Text] [Related]
19. Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017.
Brown JP; Wing K; Evans SJ; Bhaskaran K; Smeeth L; Douglas IJ
BMJ Open; 2019 Oct; 9(10):e028133. PubMed ID: 31662354
[TBL] [Abstract][Full Text] [Related]
20. Drug safety: withdrawn medications are only part of the picture.
Rawson NS
BMC Med; 2016 Feb; 14():28. PubMed ID: 26873482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
